



(43) International Publication Date
26 September 2013 (26.09.2013)

(10) International Publication Number
WO 2013/140319 A1

(51) International Patent Classification:

C07D 471/10 (2006.01) *A61P 11/00* (2006.01)
A61K 31/438 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/IB2013/052092

(22) International Filing Date:

15 March 2013 (15.03.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/612,727 19 March 2012 (19.03.2012) US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
CH-4056 Basel (CH).

(72) Inventors: **HOWSHAM, Catherine**; Novartis Pharma-
ceuticals UK Limited, Wimblehurst Road, Horsham RH12
5AB (GB). **LINDENBERG, Christian**; Novartis Pharma
AG, Postfach, CH-4002 Basel (CH). **PERLBERG, Anett**;
Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **TU-
FILLI, Nicola**; Novartis Pharma AG, Postfach, CH-4002
Basel (CH).

(74) Agent: **MUELLER, Philippe**; Novartis Pharma AG, Pat-
ent Department, CH-4002 Basel (CH).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*

(54) Title: CRYSTALLINE FORM OF A SUCCINATE SALT

(57) Abstract: This invention relates to a new crystalline form of the succinate salt of the epithelial sodium channel (ENaC) blocker 3-(3-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carbonyl}-benzenesulfonylamino)-propionic acid dipropylcarbamoylmethyl ester, pharmaceutical compositions comprising said crystalline form, uses of said crystalline form and pharmaceutical compositions, and methods for preparing said crystalline form.



WO 2013/140319 A1